Contents

Asterisks preceding the title refer to studies in humans.

189 Frequency of Fish Tumors Found in a Polluted Watershed as Compared to Nonpolluted Canadian Waters. Eric R. Brown, James J. Hazdra, Louis Keith, Irving Greenspan, J. B. G. Kwapinski, and Parker Beamer.

199 Delayed Cutaneous Hypersensitivity to Cell-free Tumor Antigens. E. Carmack Holmes, Ralph A. Reisfeld, and Donald L. Morton.


234 Ultrastructural Effects of 5-Bromodeoxyuridine and 5-Fluorouracil in Drosophila. T. M. Rizki, Rose M. Rizki, and Mary Ann Lommen.

249 * Activities and Isoenzyme Patterns of Some Enzymes of Glucose Metabolism in Human Primary Malignant Hepatoma. D. Balinsky, E. Cayanis, E. W. Geddes, and I. Bersohn.


269 Ultrastructural, Histological, and Biochemical Alterations Produced by 12-O-Tetradecanoylphorbol-13-acetate on Mouse Epidermis and Their Relevance to Skin Tumor Promotion. Alberto N. Raick.

287 Chondral Dysplasia Induced by Zirconium and Hafnium. Walter B. Shelley.

293 Comparative Studies of Subcutaneous and Intradermal Leukemic Tumors in Guinea Pigs. Ludwik Gross, Dorothy G. Feldman, Theodore Ehrenreich, Yolande Dreyfuss, and Lorraine A. Moore.

302 Mutagenic Properties of Benzo(a)pyrene and Its Methylated Derivatives in Relation to the Molecular Mechanisms of Hydrocarbon Carcinogenesis. O. G. Fahmy and Myrtle J. Fahmy.

310 Modified Nucleosides with Antineoplastic Activity as Inhibitors of an Enzyme Containing Adenosine within Its Coenzyme. George L. Trisch.


323 Inhibition of Transfer and Ribosomal RNA Methylyases by Polyinosinate. Ming C. Liu, John B. Hunt, Don W. Smith, and Robert B. Hurlbert.

326 Transplantability and Biological Behavior of Mouse Liver Tumors Induced by Ethylnitrosourea. A. P. Kyriazis and S. D. Vesselinovitch.


342 Radioiron Incorporation by a Transplantable Lymphoid Tumor. Francis W. Chandler, Jr., and Oscar J. Fletcher, Jr.


The 1972 Albert Lasker Medical Research Awards were extended to 17 individuals, for 7 categories of accomplishment in clinical cancer chemotherapy: (1) Use of drugs in cures of gestational choriocarcinoma (Li and Hertz). (2) Use of drugs in long-term disease-free survivors with Burkitt's tumor (Burkitt, Burchenal, Ngu, and Ziegler). (3) Use of topical chemotherapy and enhancement of host response for cures in skin cancers (Klein). (4) Use of combination drug therapy resulting in prolonged survival, in acute lymphatic leukemia (Frei, Freireich, Holland, and Pinkel). (5) Use of combination drug therapy, resulting in prolonged survival, in Hodgkin's disease (Frei, Carbone, and DeVita). (6) Treatment of mycosis fungoids, with topical chemotherapy and enhancement of host response (Van Scott). (7) Supportive measures in treatment of toxicity, infection, and hemorrhage, due to side effects of drugs (Djerassi and Freireich).

A special Award was presented to Dr. C. Gordon Zubrod of the National Cancer Institute, for his leadership in the National Cancer Institute program of chemotherapy. The group picture of the awards ceremonies, held on November 16, 1972, in New York, shows: Left to right, seated in first row: Dr. Isaac Djerassi, Director of Research Hematology at Mercy Catholic Medical Center ( Fitzgerald Division), Darby, Pa.; Dr. Edmund Klein, Chief of Department of Dermatology at Roswell Park Memorial Institute, Buffalo, N. Y.; Mrs. Albert D. Lasker, President of the Albert and Mary Lasker Foundation; Dr. Sidney Farber, Chairman of the Awards Jury; also President and Director of the Children's Cancer Research Foundation, Boston, Mass.; Mrs. Alice Fordyce, Vice President of the Albert and Mary Lasker Foundation; Special Award Winner, Dr. C. Gordon Zubrod, Director of the Division of Cancer Treatment at the National Cancer Institute, Bethesda, Md.; Dr. Roy Hertz, Professor of Obstetrics and Gynecology and Director of Clinical Research at New York Medical College, Valhalla, N. Y. Seated in second row: Dr. Min Chiu Li, Director of Medical Research at Nassau Hospital, Mineola, N. Y.; Dr. Eugene J. Van Scott, Professor of Dermatology at the Skin and Cancer Hospital at Temple University, Philadelphia, Pa.; Dr. Paul P. Carbone, Associate Scientific Director for Medical Oncology at the National Cancer Institute and National Institutes of Health, Bethesda, Md.; Dr. John L. Ziegler, Director at Uganda Cancer Institute, Kampala, Uganda, Africa; Dr. Joseph H. Burchenal, Associate Director of Clinical Investigation at Memorial Hospital for Cancer and Allied Diseases, New York, N. Y.; Mr. Denis Burkitt, Surgeon at Medical Research Council, London, England; Dr. Emil J. Freireich, Associate Professor of Medicine and Chief of Research Hematology at the University of Texas, Houston, Texas. Standing: Dr. Emil Frei, III, Physician-in-Chief at Children's Cancer Research Foundation, Boston, Mass.; Dr. Vincent T. DeVita, Jr., Chief of Medicine Branch at National Cancer Institute, Bethesda, Md.; Dr. V. Anomah Ngu, Professor of Surgery at Centre of Health Sciences, Yaounde, United Republic of Cameroon, Africa; Dr. Donald Pinkel, Medical Director at St. Jude Children's Research Hospital, Memphis, Tenn. Absent was Dr. James F. Holland, Director, Cancer Clinical Research Center at Roswell Park Memorial Institute, Buffalo, N. Y.
